ME: 23andMe Holding Co. Stock

by  •  • Comments Off on ME: 23andMe Holding Co. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 29.39
Enterprise Value ($M) -49.96
Book Value ($M) 70.22
Book Value / Share 3.56
Price / Book 0.42
NCAV ($M) -45.62
NCAV / Share -2.31
Price / NCAV -0.64

Profitability (mra)
Return on Invested Capital (ROIC) -2.93
Return on Assets (ROA) -0.63
Return on Equity (ROE) -1.02

Liquidity (mrq)
Quick Ratio 0.96
Current Ratio 1.11

Balance Sheet (mrq) ($M)
Current Assets 161.58
Assets 277.42
Liabilities 207.20
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
15 hours ago 13D/A ABeeC 2.0, LLC 21.90 0.00
02-24 13G/A Zentree Investments Ltd 10.00
11-15 13D/A Glaxosmithkline Plc 9.50 -95.00
11-12 13G/A Vanguard Group Inc 4.58 0.00
10-21 13G/A Sc Us (ttgp), Ltd. 3.90 -95.00
07-08 13G/A BlackRock, Inc. 1.40 -79.27

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-02-06 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 o TRANSITION REPOR
2024-11-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 o TRANSITION REPO
2024-08-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 o TRANSITION REPORT PU
2024-05-30 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-03-07 23,835 110,539 21.56
2025-03-06 44,233 148,102 29.87
2025-03-05 58,205 270,015 21.56
2025-03-04 122,546 374,975 32.68

(click for more detail)

Similar Companies
LTRN – Lantern Pharma Inc. MBIO – Mustang Bio, Inc.
MBRX – Moleculin Biotech, Inc. MEIP – MEI Pharma, Inc.
MIRA – MIRA Pharmaceuticals, Inc.


Financial data and stock pages provided by
Fintel.io